Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors.

Autor: Mazzaschi G; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Perrone F; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Maglietta G; Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy., Favari E; Food and Drug Department, University of Parma, Parma, Italy., Verzè M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Pluchino M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Minari R; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Pecci F; Department of Medicine and Surgery, University of Parma, Parma, Italy., Gnetti L; Pathology Unit, University Hospital of Parma, Parma, Italy., Campanini N; Pathology Unit, University Hospital of Parma, Parma, Italy., Silini EM; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Pathology Unit, University Hospital of Parma, Parma, Italy., De Filippo M; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Radiology Unit, University Hospital of Parma, Parma, Italy., Maffezzoli M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Giudice GC; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Testi I; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Quaini F; Department of Medicine and Surgery, University of Parma, Parma, Italy., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy.

Publikováno v: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2024 Nov-Dec 01; Vol. 47 (9), pp. 388-394. Date of Electronic Publication: 2024 Jul 11.

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).

Autor: Catalano F; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy., Brunelli M; Pathology Unit, Department of Diagnostics & Public Health, University & Hospital Trust of Verona, 37124, Verona, Italy., Signori A; Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genoa, 16132, Genoa, Italy., Rescigno P; Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, Italy.; Translational & Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne,  NE1 7RU, UK., Buti S; Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.; Medical Oncology Unit, University Hospital of Parma, 43126, Parma, Italy., Galli L; Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana,    56126, Pisa, Italy., Spada M; UOC Oncologia Medica, Istituto Fondazione G. Giglio, 90015,  Cefalù, Italy., Masini C; Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, 42122, Reggio Emilia, Italy., Galuppini F; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, 35128, Padua, Italy., Vellone VG; Pathology Unit, IRCCS Istituto Giannina Gaslini, 16147, Genoa, Italy.; Department of Integrated Surgical & Diagnostic Sciences (DISC), University of Genoa, 16132, Genoa, Italy., Gaggero G; Pathology Unit, IRCCS Istituto Giannina Gaslini, 16147, Genoa, Italy., Maruzzo M; Oncology Unit 1, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padua, Italy., Merler S; Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona & Verona University & Hospital Trust, Verona, 37134, Italy., Vignani F; Division of Medical Oncology, Ordine Mauriziano Hospital, 10128, Turin, Italy., Cavo A; Oncology Unit, Villa Scassi Hospital, 16149, Genoa, Italy., Bimbatti D; Oncology Unit 1, Istituto Oncologico Veneto IOV-IRCCS, 35128, Padua, Italy., Milella M; Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona & Verona University & Hospital Trust, Verona, 37134, Italy., Dei Tos AP; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, 35128, Padua, Italy., Sbaraglia M; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, 35128, Padua, Italy., Murianni V; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy., Damassi A; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy., Cremante M; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy., Maffezzoli M; Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy., Llaja Obispo MA; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy., Banna GL; Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.; School of Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2UP, UK., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy., Rebuzzi SE; Medical Oncology Unit, Ospedale San Paolo, 17100, Savona, Italy.; Department of Internal Medicine & Medical Specialties (Di.M.I.), University of Genoa, 16132, Genoa, Italy.

Publikováno v: Future oncology (London, England) [Future Oncol] 2024 May 03, pp. 1-19. Date of Electronic Publication: 2024 May 03.

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.

Autor: Maffezzoli M; Department of Medicine and Surgery, University of Parma, Parma, Italy. michele.maffezzoli@unipr.it.; Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy. michele.maffezzoli@unipr.it., Santoni M; Oncology Unit, Macerata Hospital, 62100, Macerata, Italy., Mazzaschi G; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy., Rodella S; Department of Medicine and Surgery, University of Parma, Parma, Italy., Lai E; Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Maruzzo M; Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Basso U; Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Bimbatti D; Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Iacovelli R; Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Anghelone A; Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Rebuzzi SE; Medical Oncology Unit, Ospedale San Paolo, Savona, Italy.; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genoa, Italy., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Lolli C; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Rosellini M; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Nasso C; Medical Oncology, Ospedale Santa Corona, 17027, Pietra Ligure, Italy., Acunzo A; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy., Silini EM; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Pathology Unit, University Hospital of Parma, Parma, Italy., Quaini F; Department of Medicine and Surgery, University of Parma, Parma, Italy., De Filippo M; Department of Medicine and Surgery, Section of Radiology, University of Parma, Parma, Italy., Brunelli M; Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy., Banna GL; Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK., Rescigno P; Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK., Signori A; Section of biostatistics, Department of Health Sciences (DISSAL), University of Genova, Genoa, Italy., Buti S; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy.

Publikováno v: Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Apr; Vol. 41 (2), pp. 117-129. Date of Electronic Publication: 2024 Feb 16.

Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.

Autor: Perrone F; Medical Oncology Unit, University Hospital of Parma, Parma.; Department of Medicine & Surgery, Parma, University of Parma, Parma., Pecci F; Clinical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona., Maffezzoli M; Medical Oncology Unit, University Hospital of Parma, Parma.; Department of Medicine & Surgery, Parma, University of Parma, Parma., Giudice GC; Medical Oncology Unit, University Hospital of Parma, Parma.; Department of Medicine & Surgery, Parma, University of Parma, Parma., Cognigni V; Clinical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona., Mazzaschi G; Medical Oncology Unit, University Hospital of Parma, Parma.; Department of Medicine & Surgery, Parma, University of Parma, Parma., Cantini L; Fortrea, Inc., Durham, NC, USA., Santamaria L; Clinical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona., Paoloni F; Clinical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona., Bruno Rocchi ML; Biomolecular Sciences Department, University of Urbino, Urbino, Italy., Coriano' M; Medical Oncology Unit, University Hospital of Parma, Parma., Acunzo A; Medical Oncology Unit, University Hospital of Parma, Parma.; Department of Medicine & Surgery, Parma, University of Parma, Parma., Quaini F; Department of Medicine & Surgery, Parma, University of Parma, Parma., Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma.; Department of Medicine & Surgery, Parma, University of Parma, Parma., Kamal SS; Fortrea, Inc., Durham, NC, USA., Berardi R; Clinical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma.; Department of Medicine & Surgery, Parma, University of Parma, Parma.

Publikováno v: Immunotherapy [Immunotherapy] 2024; Vol. 16 (13), pp. 859-868. Date of Electronic Publication: 2024 Aug 06.

Prognostic models for patients with metastatic urothelial carcinoma: why use them?

Autor: Maffezzoli M; Unit of Medical Oncology, University Hospital of Parma, Parma, Italy - michele.maffezzoli@unipr.it., Campobasso D; Department of Urology, University Hospital of Parma, Parma, Italy., Rebuzzi SE; Unit of Medical Oncology, San Paolo Hospital, Savona, Italy.; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy., Banna GL; Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Fornarini G; Unit of Medical Oncology, IRCCS San Martino University Hospital, Genoa, Italy., Signori A; Section of Biostatistics, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy., Rescigno P; Center for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK., Buti S; Unit of Medical Oncology, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy.

Publikováno v: Minerva urology and nephrology [Minerva Urol Nephrol] 2023 Aug; Vol. 75 (4), pp. 419-421. Date of Electronic Publication: 2023 May 11.